Literature DB >> 3550084

Effectiveness of amantadine in reducing relapses in multiple sclerosis.

G S Plaut.   

Abstract

Fifty-three patients with multiple sclerosis were assessed in a double-blind multicentre study for the effect of amatadine. The patients were observed in general practices for up to four years. Relapses occurred in 5 of the 24 patients treated with amantadine and in 14 of the 29 placebo-treated patients. Neurological deterioration was not significantly different in the two groups.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3550084      PMCID： PMC1290678          DOI： 10.1177/014107688708000210

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   18.000


  28 in total

1.  On the evaluation of disability in multiple sclerosis.

Authors:  J F KURTZKE
Journal:  Neurology       Date:  1961-08       Impact factor: 9.910

Review 2.  Epidemiology of multiple sclerosis.

Authors:  E D Acheson
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

3.  Intrathecal cytarabine in multiple sclerosis.

Authors:  M Gore; R Buckman; G Stern
Journal:  Lancet       Date:  1979-07-28       Impact factor: 79.321

4.  Screening of children at risk of multiple sclerosis.

Authors:  E J Field; G Joyce
Journal:  Lancet       Date:  1977-07-16       Impact factor: 79.321

5.  Recovery of Paramyxovirus from the jejunum of patients with multiple sclerosis.

Authors:  I Prasad; J D Broome; L P Pertschuk; J Gupta; A W Cook
Journal:  Lancet       Date:  1977-05-28       Impact factor: 79.321

6.  Clinical immunology.

Authors: 
Journal:  Lancet       Date:  1976-08-28       Impact factor: 79.321

7.  Isolation of an infectious agent from bone-marrows of patients with multiple sclerosis.

Authors:  D N Mitchell; J S Porterfield; R Micheletti; L S Lange; K K Goswami; P Taylor; J P Jacobs; D J Hockley; A J Salsbury
Journal:  Lancet       Date:  1978-08-19       Impact factor: 79.321

8.  Controlled trial of cysteamine in treatment of acute paracetamol (acetaminophen) poisoning.

Authors:  A P Douglas; A N Hamlyn; O James
Journal:  Lancet       Date:  1976-01-17       Impact factor: 79.321

9.  Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit.

Authors:  D W Paty; H K Cousin; S Read; K Adlakha
Journal:  Acta Neurol Scand       Date:  1978-07       Impact factor: 3.209

10.  Decreased percentage of polymorphonuclear neutrophils in mouse peripheral blood after inoculation with material from multiple sclerosis patients.

Authors:  R I Carp; P C Licursi; P A Merz; G S Merz
Journal:  J Exp Med       Date:  1972-09-01       Impact factor: 14.307
View more
  10 in total

Review 1.  Amantadine for fatigue in multiple sclerosis.

Authors:  E Pucci; P Branãs; R D'Amico; G Giuliani; A Solari; C Taus
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.

Authors:  S Rossi; T Lo Giudice; V De Chiara; A Musella; V Studer; C Motta; G Bernardi; G Martino; R Furlan; A Martorana; D Centonze
Journal:  Br J Pharmacol       Date:  2012-02       Impact factor: 8.739

3.  Interleukin-1β alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis.

Authors:  Georgia Mandolesi; Alessandra Musella; Antonietta Gentile; Giorgio Grasselli; Nabila Haji; Helena Sepman; Diego Fresegna; Silvia Bullitta; Francesca De Vito; Gabriele Musumeci; Claudio Di Sanza; Piergiorgio Strata; Diego Centonze
Journal:  J Neurosci       Date:  2013-07-17       Impact factor: 6.167

4.  Abnormal NMDA receptor function exacerbates experimental autoimmune encephalomyelitis.

Authors:  G Grasselli; S Rossi; A Musella; A Gentile; S Loizzo; L Muzio; C Di Sanza; F Errico; G Musumeci; N Haji; D Fresegna; H Sepman; V De Chiara; R Furlan; G Martino; A Usiello; G Mandolesi; D Centonze
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 5.  Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis.

Authors:  Georgia Mandolesi; Antonietta Gentile; Alessandra Musella; Diego Fresegna; Francesca De Vito; Silvia Bullitta; Helena Sepman; Girolama A Marfia; Diego Centonze
Journal:  Nat Rev Neurol       Date:  2015-11-20       Impact factor: 42.937

6.  Finding disease candidate genes by liquid association.

Authors:  Ker-Chau Li; Aarno Palotie; Shinsheng Yuan; Denis Bronnikov; Daniel Chen; Xuelian Wei; Oi-Wa Choi; Janna Saarela; Leena Peltonen
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

Review 7.  Glutamate receptors in neuroinflammatory demyelinating disease.

Authors:  Christopher Bolton; Carolyn Paul
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

Review 8.  Neuroendocrine immunoregulation in multiple sclerosis.

Authors:  Nathalie Deckx; Wai-Ping Lee; Zwi N Berneman; Nathalie Cools
Journal:  Clin Dev Immunol       Date:  2013-12-08

Review 9.  Silent Free Fall at Disease Onset: A Perspective on Therapeutics for Progressive Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Front Neurol       Date:  2018-11-27       Impact factor: 4.003

10.  Siponimod (BAF312) prevents synaptic neurodegeneration in experimental multiple sclerosis.

Authors:  Antonietta Gentile; Alessandra Musella; Silvia Bullitta; Diego Fresegna; Francesca De Vito; Roberta Fantozzi; Eleonora Piras; Francesca Gargano; Giovanna Borsellino; Luca Battistini; Anna Schubart; Georgia Mandolesi; Diego Centonze
Journal:  J Neuroinflammation       Date:  2016-08-26       Impact factor: 8.322
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.